patients with stable drug substitution therapy
Showing 1 - 25 of >10,000
Drug Resistant Epilepsy Trial in Jakarta Pusat, Jakarta (Valproic acid, Carbamazepin, Phenytoin)
Recruiting
- Drug Resistant Epilepsy
- Valproic acid
- +5 more
-
Jakarta Pusat, Jakarta, Indonesia
- +2 more
Jan 14, 2023
HIV, Human Immunodeficiency Virus Trial in San Francisco (PRO 140 350mg weekly SQ injection.)
Completed
- HIV
- Human Immunodeficiency Virus
- PRO 140 350mg weekly SQ injection.
-
San Francisco, CaliforniaQuest Clinical Research
Sep 28, 2021
Prevent HIV, Initiate Opioid Substitution Therapy, and Reduce
Active, not recruiting
- HCV
- +2 more
- Evaluate model of care for HCV-infected adults with on-going opioid misuse
-
Washington, District of Columbia
- +1 more
Feb 2, 2022
Human Immuno-deficiency Virus (HIV) Disease Trial (Budigalimab, Placebo for Budigalimab, ABBV-382)
Not yet recruiting
- Human Immuno-deficiency Virus (HIV) Disease
- Budigalimab
- +3 more
- (no location specified)
Sep 5, 2023
Metastatic Microsatellite-stable Colorectal Cancer Trial in China (Experimental drug, Control Rx)
Recruiting
- Metastatic Microsatellite-stable Colorectal Cancer
- Experimental drug
- Control Rx
-
Hefei, Anhui, China
- +11 more
Mar 13, 2023
Opioid Use Disorder, Moderate Trial in Berlin, New York (Levomethadone HCl, Methadone, Morphine Sulfate)
Recruiting
- Opioid Use Disorder, Moderate
- Levomethadone HCl
- +4 more
-
Berlin, New Jersey
- +1 more
Mar 16, 2022
Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction Trial in Korea, Republic of (CX-ISAR, Orsiro,
Completed
- Stable Angina
- +2 more
- 3-months DAPT
- 1-year DAPT
-
Busan, Korea, Republic of
- +11 more
Jan 8, 2023
Angina, Stable, Acute Coronary Syndrome, Drug-Eluting Stents Trial in Beijing, Xuzhou, Chengdu (CYP2C19 genotype testing)
Recruiting
- Angina, Stable
- +3 more
- CYP2C19 genotype testing
-
Beijing, Beijing, China
- +11 more
Nov 4, 2021
Central Diabetes Insipidus (cDI) Trial in Basel (Intranasal OXT, Placebo nasal spray)
Not yet recruiting
- Central Diabetes Insipidus (cDI)
- Intranasal OXT
- Placebo nasal spray
-
Basel, SwitzerlandUniversity Hospital Basel, Department of Endocrinology, Diabetes
Sep 6, 2023
Diabetes Type 2 With Proteinuria, Diabetes, Type 2, Diabetes Trial (drug, device, diagnostic test, behavioral)
Not yet recruiting
- Diabetes Mellitus Type 2 With Proteinuria
- +12 more
- Empagliflozin 10 MG
- +6 more
- (no location specified)
Oct 17, 2023
Atrial Fibrillation, HFpEF - Heart Failure With Preserved Ejection Fraction Trial (Radiofrequency catheter ablation (RFCA),
Not yet recruiting
- Atrial Fibrillation
- HFpEF - Heart Failure With Preserved Ejection Fraction
- Radiofrequency catheter ablation (RFCA)
- Medical Therapy
- (no location specified)
Nov 5, 2023
Hepatitis C Trial in Melbourne, Dundee, Cardiff (Reach Pathway, Education-only Pathway)
Completed
- Hepatitis C
- Reach Pathway
- Education-only Pathway
-
Melbourne, Australia
- +2 more
Oct 12, 2021
CD20+ Aggressive B-Cell Lymphoma Trial in Germany (Conventional Vincristine, Liposomal Vincristine, Ricover-scheme rituximab)
Active, not recruiting
- CD20+ Aggressive B-Cell Lymphoma
- Conventional Vincristine
- +3 more
-
Homburg, Saarland, Germany
- +125 more
Nov 11, 2022
Hypercholesterolemia, Atherosclerotic Ischemic Disease Trial in Heidelberg, London (lerodalcibep, Inclisiran)
Enrolling by invitation
- Hypercholesterolemia
- Atherosclerotic Ischemic Disease
- lerodalcibep
- Inclisiran
-
Nantes, Cedex 01, France
- +6 more
Nov 3, 2022
Substance Use Disorders, Prenatal Care, Pregnancy Outcome Trial in Hamilton (Monthly Pregnancy Screening, Usual Care)
Terminated
- Substance Use Disorders
- +2 more
- Monthly Pregnancy Screening
- Usual Care
-
Hamilton, Ontario, CanadaThe Hamilton Clinic
Apr 12, 2022
Graves Disease, Relapse, Treatment Trial in Nanjing (Methimazole)
Recruiting
- Graves Disease
- +3 more
-
Nanjing, Chinathe First Affiliated Hospital of Nanjing Medical University
Jul 21, 2022
Hepatitis C Trial in Australia (Campaign days)
Recruiting
- Hepatitis C
- Campaign days
-
Campbelltown, New South Wales, Australia
- +7 more
Mar 30, 2022
Adrenal Insufficiency Trial in Tunis (Hydrocortisone (capsule))
Completed
- Adrenal Insufficiency
- Hydrocortisone (capsule)
-
Tunis, Tunisia
- +1 more
Jul 11, 2022
Cardiovascular Diseases, Hyper-LDL-cholesterolemia Trial in Cincinnati (lerodalcibep)
Active, not recruiting
- Cardiovascular Diseases
- Hyper-LDL-cholesterolemia
-
Cincinnati, Ohio
- +2 more
Nov 3, 2022
Evaluating the Chain of Addiction Care (CAC)
Recruiting
- Hepatitis C, Chronic
- Substance Use Disorders
-
Nijmegen, Gelderland, NetherlandsRadboudumc
May 31, 2022
Cardiovascular Risk Factor, Cardiovascular Diseases, Cardiovascular Stroke Trial in India, Israel, United States (lerodalcibep,
Active, not recruiting
- Cardiovascular Risk Factor
- +3 more
- lerodalcibep
- Placebo
-
Cincinnati, Ohio
- +5 more
Nov 3, 2022
Heterozygous Familial Hypercholesterolemia Trial in Worldwide (lerodalcibep)
Active, not recruiting
- Heterozygous Familial Hypercholesterolemia
-
Cincinnati, Ohio
- +6 more
Nov 3, 2022
Coronary Artery Disease, Prediabetic State Trial in Seoul (Dapagliflozin 10mg, Lifestyle modification)
Terminated
- Coronary Artery Disease
- Prediabetic State
- Dapagliflozin 10mg
- Lifestyle modification
-
Seoul, Korea, Republic ofAsan Medical Center
Sep 21, 2022
Hepatitis C Trial in Darlinghurst, Kingswood, Newcastle (Grazoprevir/elbasvir)
Terminated
- Hepatitis C
-
Darlinghurst, New South Wales, Australia
- +4 more
Feb 21, 2020